Celldex Therapeutics
CLDX · Nasdaq · United States
Share price · CLDX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CLDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026-11.6%
- 14 Sep 2026+6.2%
Nothing announced by CLDX that day or the session before.
- 5 Aug 2026+5.1%
Nothing announced by CLDX that day or the session before.
- 29 Jul 2026+5.4%
Nothing announced by CLDX that day or the session before.
- 16 Jul 2026-7.6%
- 7 Jul 2026+5.2%
Nothing announced by CLDX that day or the session before.
- 29 Jun 2026+6.2%
- 12 Jun 2026+4.4%
Nothing announced by CLDX that day or the session before.
- 25 Feb 2026+24.1%
- 12 Jan 2026-6.2%
Nothing announced by CLDX that day or the session before.
Share of unusual movement by asset
For each asset, the share of CLDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
barzolvolimabevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 8% |
| Other company news (earnings, financing, releases naming no asset) | — | 18% |
| Sessions with no dated event | — | 74% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | KITMonoclonal antibody | Atopic DermatitisChronic Spontaneous UrticariaUrticaria Chronic Inducible Urticaria | |
| Phase 1 | TSLP + SCF/KITMultispecific antibody | Asthma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
June 2028 (1)
What to watch
September 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $67M | $27M+ $623M short-term inv. | $76M-$65M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | <$0.1M | $68M | $47M+ $670M short-term inv. | $74M-$57M operating cash flow | report ↗ |
| 2026-Q1 | <$0.1M | $73M | $452M | $79M | report ↗ |
| 2025-Q3 | — | $63M | $36M+ $547M short-term inv. | $67M-$49M operating cash flow | report ↗ |
| 2025-Q2 | $0.7M | $54M | $23M+ $607M short-term inv. | $57M-$44M operating cash flow | report ↗ |
| 2025-Q1 | $0.7M | $53M | $17M+ $656M short-term inv. | $54M-$54M operating cash flow | report ↗ |
| 2024-Q3 | $3.2M | $45M | $36M+ $720M short-term inv. | $42M-$55M operating cash flow | report ↗ |
| 2024-Q2 | $2.5M | $40M | $43M+ $760M short-term inv. | $36M-$29M operating cash flow | report ↗ |
| 2024-Q1 | $0.2M | $32M | $115M+ $709M short-term inv. | $33M-$41M operating cash flow | report ↗ |
| 2023-Q3 | $1.5M | $35M | $21M+ $214M short-term inv. | —-$19M operating cash flow | report ↗ |
| 2023-Q2 | $0.3M | $26M | $28M+ $224M short-term inv. | —-$27M operating cash flow | report ↗ |
| 2023-Q1 | $1.0M | $27M | $54M+ $224M short-term inv. | —-$29M operating cash flow | report ↗ |
| 2022-Q3 | $0.4M | $22M | $19M+ $305M short-term inv. | —-$35M operating cash flow | report ↗ |
| 2022-Q2 | $0.2M | $21M | $28M+ $328M short-term inv. | —-$22M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $17M | $25M+ $355M short-term inv. | —-$25M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $14M | $72M+ $351M short-term inv. | —-$16M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.6M | $245M | $29M+ $490M short-term inv. | $65M-$211M operating cash flow | report ↗ |
For fiscal year 2025, Celldex reported revenue of $1.55M, down 77.9% YoY, with R&D spend of $245.07M, up 49.8% YoY. Cash and equivalents stood at $28.87M, and the company reported a net loss of $258.76M with quarterly net burn of $258.76M.
Celldex advanced its clinical pipeline during the period. The Phase 3 CSU program for barzolvolimab completed enrollment in February 2026 with topline data expected in Q4 2026, a Phase 3 study in cold urticaria and symptomatic dermographism was initiated in December 2025, and Phase 2 studies in prurigo nodularis and atopic dermatitis completed enrollment with topline data expected in summer 2026 and late 2026, respectively. The CDX-622 Phase 1a study completed enrollment, with multiple ascending dose and subcutaneous data anticipated in Q3 2026, and a Phase 1 proof-of-mechanism study in mild to moderate asthma was initiated in January 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $7.0M | $164M | $28M+ $697M short-term inv. | $39M-$158M operating cash flow | report ↗ |
| 2023-FY | $6.9M | $118M | $35M+ $389M short-term inv. | $35M-$107M operating cash flow | report ↗ |
| 2022-FY | $2.4M | $82M | $29M+ $276M short-term inv. | $28M-$104M operating cash flow | report ↗ |
| 2021-FY | $4.7M | $53M | $39M+ $369M short-term inv. | $18M-$61M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($121K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-25 | PENNER HARRY JR · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | CONRAD HERBERT J · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | MARINO JAMES J · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | Brownlie Keith L · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | Cohen Cheryl · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | NEIL GARRY ARTHUR · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | Jain Rita · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
| 2026-06-25 | Torres Denice · director | Award / grant (derivative) | 26,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 228 reporting institutions held 72.8M shares ($2.2B, 92.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | WELLINGTON MANAGEMENT GROUP LLP | 8,560,476 | $271.5M |
| 2 | Kynam Capital Management, LP | 5,840,567 | $185.3M |
| 3 | BlackRock, Inc. | 5,369,885 | $170.3M |
| 4 | FMR LLC | 3,749,048 | $118.9M |
| 5 | Point72 Asset Management, L.P. | 3,229,939 | $102.5M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,960,895 | $93.9M |
| 7 | STATE STREET CORP | 2,804,168 | $88.9M |
| 8 | Commodore Capital LP | 2,696,616 | $85.5M |
| 9 | Eversept Partners, LP | 1,788,016 | $56.7M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,688,074 | $53.6M |
| 11 | BRAIDWELL LP | 1,356,082 | $43.0M |
| 12 | Deep Track Capital, LP | 1,283,979 | $40.7M |
| 13 | MILLENNIUM MANAGEMENT LLC | 1,253,532 | $39.8M |
| 14 | Vestal Point Capital, LP | 1,224,165 | $38.8M |
| 15 | NOVO HOLDINGS A/S | 1,200,000 | $38.1M |